Artivion (NYSE:AORT) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsBill Plovanic - Managing Director and Healthcare Equity ResearchDaniel Stauder - VP of Equity ResearchLance Berry - COO and CFOLane Morgan - Associate Vice PresidentPat Mackin - CEOConference Call ParticipantsJohn McCalley - Equity Research AnalystMike Matson - Managing Director and Senior Equity Research AnalystNone - AnalystNone - AnalystOperatorGood afternoon, and welcome to the Artivion Q4 and Year-end 2025 Earn ...

Financial Data and Key Metrics Changes - Revenues for Q4 2025 were $4.9 million, a decrease from $31 million in Q4 2024, primarily due to lower unit sales [13] - Full year revenues for 2025 were $27.5 million, down from $41.8 million in 2024, driven by reduced sales to the largest customer [16] - Gross profit for Q4 2025 was $1.9 million, or 38.8% of revenues, compared to $7.1 million, or 54.2% in Q4 2024 [14] - Net loss for Q4 2025 was $3.2 million, or a loss of $0.19 per share, compared to net income of $1.5 million, or $0.09 per diluted share in Q4 2024 [15] - Full year net loss for 2025 was $7.7 million, or a loss of $0.47 per share, compared to net income of $6.6 million, or $0.41 per diluted share in 2024 [18] Business Line Data and Key Metrics Changes - The company shipped 14 units in Q4 2025, with 8 in the U.S. and 6 internationally, with no sales to the largest customer [5][22] - Utilization across the Fair Deal Agreement program increased substantially, with treatments up more than eightfold year-over-year and the number of patients treated increasing by over 250% [6] Market Data and Key Metrics Changes - International sales were strong in Q4 2025, with shipments to China and a growing demand in Asia, particularly in Taiwan and South Korea [7][28] - The company expects international markets to remain a significant part of its growth strategy, with Brazil clearance anticipated in 2026 [28] Company Strategy and Development Direction - The introduction of new CPT codes for SRT and IG-SRT technology is expected to enhance physician reimbursement and support broader adoption [4][20] - The company aims to achieve full-year profitability in 2026, supported by a diversified customer base and expanding international opportunities [8][19] - A disciplined approach to scaling the sales organization is being implemented, with plans to hire additional sales representatives [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with greater clarity and control over the business, emphasizing the positive impact of new reimbursement codes [20] - The company is focused on educating physicians about the new reimbursement codes to drive adoption and growth [5][8] Other Important Information - The company ended 2025 with $22.1 million in cash and cash equivalents, unchanged from the previous year, and no outstanding debt [18] - Research and development expenses for 2025 increased to $7.8 million, primarily due to higher costs related to billing and reimbursement efforts [17] Q&A Session Summary Question: Guidance on revenue growth excluding the largest customer - Management confirmed that projections for 2026 do not include expectations from the largest customer, as they are reevaluating their model moving forward [22][23] Question: Update on TDI and FDA approval - Management indicated ongoing efforts with the FDA regarding TDI but could not provide a timeline for approval [25] Question: International demand outlook - Management highlighted strong demand in China and growth in Taiwan, with expectations for further expansion in Asia and South America [27][28] Question: Reaction to reimbursement and system mix - Management noted a shift towards outright purchases and leasing options due to improved reimbursement clarity, with a stronger focus on SRT technology [37][41] Question: Interest from private equity-backed groups - Increased interest from private equity groups was noted, with a reevaluation of acquisition strategies due to clearer reimbursement pathways [42]

Applied Materials (NasdaqGS:AMAT) Q1 2026 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsBlayne Curtis - Managing DirectorBrice Hill - CFOCJ Muse - Senior Managing DirectorGary Dickerson - CEOHarlan Sur - Executive Director of Equity ResearchKrish Sankar - Managing DirectorMark Lipacis - Senior Managing DirectorMelissa Weathers - Director of Equity ResearchMike Sullivan - Corporate VP of Investor RelationsTimothy Arcuri - Managing DirectorVivek Arya - Managing DirectorConference Call Partic ...

Financial Data and Key Metrics Changes - Fourth quarter revenue reached $122 million, a 30% increase year-over-year, with 40% from systems and 60% from recurring revenue [5][10] - Full year revenue for 2025 was $453 million, up 13% year-over-year, indicating a market recovery trajectory [6][10] - Gross margin for Q4 was 40.8%, lower than guidance due to one-time inventory charges [11] - Cash and investments increased by $286 million during Q4, totaling $484 million at year-end [12] Business Line Data and Key Metrics Changes - Recurring revenue grew 4% quarter-over-quarter and 25% year-over-year, representing about 60% of total revenue in Q4 [4][5] - Systems demand increased 47% quarter-over-quarter, driven by higher equipment orders from major global customers [4] - The top ten customers accounted for approximately 63% of Q4 bookings, indicating healthy diversification [5] Market Data and Key Metrics Changes - Test utilization trends improved, with estimated utilization at 76% by the end of December, with computing at 78% and automotive at 75% [7] - Increased activity noted in automotive and industrial semiconductor sectors, alongside strong demand from RF and connectivity device customers [4][9] Company Strategy and Development Direction - The company is focusing on high-performance computing, HBM memory, and AI-related high-growth opportunities [11][12] - A strategic convertible notes offering was completed to strengthen the balance sheet and support strategic initiatives [12] - The company aims to support R&D investments enabling design wins in compute markets, including AI data center infrastructure [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating regional shifts and aligning with customers investing in long-term technology transitions [9] - The outlook for Q1 2026 anticipates revenue to be seasonally flat with Q4, with recurring revenue expected to represent about 60% of total revenue [14] - Management expects continued growth in 2026, building on the 13% revenue growth in 2025 [35] Other Important Information - The company secured significant orders for new products, including a high-performance thermal configuration of the Eclipse handler and a multi-unit order for a new handler targeting automotive and AI device tests [8][9] - The company has a solid risk balance profile due to low direct exposure to China and strong customer diversification across North America, Europe, and Asia [9] Q&A Session Summary Question: Order activity in Q4 - Management noted systems orders were up 47% quarter-over-quarter, with recurring orders up 34% quarter-over-quarter, indicating strong demand [18][20] Question: Revenue from Neon high bandwidth memory - The company exited 2025 with $11 million in HBM revenue and forecasts $15 million to $20 million for 2026 [22] Question: Eclipse activity and capacity - Management confirmed capacity to meet demand for the Eclipse handler, with expectations for increased shipments in the second quarter [25][26] Question: Customer activity changes - Management observed increased demand from traditional customers and strong forecasts for the Eclipse product line in compute and mobile applications [34] Question: IDM vs. OSAT performance - Utilization rates for IDMs were slightly higher than OSATs in Q4, with expectations that OSATs may see faster growth in the first quarter [50]

Financial Data and Key Metrics Changes - In Q4 2025, the company reported gross bookings of $27 billion and revenue of $3.5 billion, both reflecting an 11% year-over-year growth [15][16] - Adjusted EBITDA for Q4 was $848 million, with a margin of 24%, representing nearly four points of margin expansion [19] - Adjusted EPS grew 58% to $3.78, driven by share repurchases and a lower tax rate [19] Business Line Data and Key Metrics Changes - B2C gross bookings reached $18.3 billion, growing 5%, while B2C revenue was $2.2 billion, up 4% [16] - B2B gross bookings surged 24% to $8.7 billion, with revenue also increasing by 24% to $1.3 billion [17] - Booked room nights increased by 9%, with strong performance in the U.S. and EMEA regions [15][16] Market Data and Key Metrics Changes - The company experienced high single-digit growth in the U.S. and low double-digit growth in EMEA and the rest of the world [5] - Consumer spending remained robust, with longer booking windows and lengths of stay compared to 2024 [5] - The company noted a slowdown in growth in the rest of the world due to geopolitical issues in Asia [15] Company Strategy and Development Direction - The company aims to enhance traveler value through improved product offerings, faster site performance, and personalized experiences using AI [6][10] - Strategic priorities include investing in growth opportunities, particularly in B2B and advertising, while maintaining operational efficiencies [8][11] - The company is focused on expanding its inventory and enhancing customer service capabilities to drive satisfaction and loyalty [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategy and ability to execute, anticipating continued growth and margin expansion in 2026 [14][24] - The company is cautious about macroeconomic uncertainties but expects strong bookings momentum entering Q1 2026 [21][22] - Management highlighted the importance of AI in capturing traveler demand and enhancing product offerings [10][71] Other Important Information - The company ended Q4 with $5.7 billion in unrestricted cash and short-term investments, maintaining a commitment to return capital to shareholders [19][21] - A quarterly dividend increase of 20% to $0.48 per share was announced [21] Q&A Session Summary Question: Enhancements in Travel Planning Process - Management emphasized the importance of personalized marketing and product features to capture travelers earlier in the planning process [26][27] Question: B2C Marketing Leverage - Management discussed achieving about 50 basis points of leverage in B2C marketing through improved targeting and efficiency [30][31] Question: Competitive Positioning of Consumer Brands - Management expressed confidence in the positioning of their brands, highlighting recent improvements and growth potential [36][38] Question: Margin Trajectory Outlook - Management indicated confidence in future margin expansion driven by effective execution and growth in B2C and B2B segments [41][43] Question: Supply Growth and Market Dynamics - Management noted a 10% growth in lodging properties and emphasized ongoing efforts to enhance supply and partnerships [49][51] Question: Traffic Changes from Google AI Features - Management reported no material changes in traffic but is actively experimenting with AI to enhance visibility and conversion [55][57] Question: B2B Growth Drivers and Margin Outlook - Management highlighted strong double-digit growth in B2B and ongoing investments that may temporarily pressure margins [64][66]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue reached $3.2 billion, a 10% increase compared to Q4 2024, while full-year revenue was $12 billion, reflecting a 9% growth versus 2024 [32][33] - Non-GAAP net income for Q4 2025 was $1.3 billion, up 24% year-over-year, resulting in earnings per share of $5.03, a 26% increase compared to the prior year [37] - The company ended 2025 with $12.3 billion in cash, cash equivalents, and marketable securities, positioning it well for future investments [37] Business Line Data and Key Metrics Changes - Cystic fibrosis (CF) therapies generated full-year 2025 growth of 7% globally, with U.S. CF revenue growing 11% year-over-year [32][33] - CASGEVY achieved $54 million in revenue in Q4 and $116 million for the full year 2025, indicating strong patient initiations and first cell collections [34] - JOURNAVX delivered $27 million in sales in Q4 and $60 million for the full year, with significant growth in quarterly prescriptions since its launch [34][35] Market Data and Key Metrics Changes - The CF population has seen a 3% annual increase over the last five years, contributing to revenue growth [20] - In Europe, reimbursement for ALYFTREK has been secured in key countries, enhancing market access [21] - The company has engaged with payers covering over 210 million lives regarding the renal pipeline, indicating strong interest and education on IgAN [60] Company Strategy and Development Direction - The company aims to expand leadership in CF, accelerate adoption of CASGEVY, and grow JOURNAVX while advancing its renal franchise [6][29] - The renal pipeline is expected to rival the scale of the CF business, with a focus on patient-centric approaches and securing reimbursement [29][30] - The company is committed to serial innovation and comprehensive patient support programs to enhance access to its therapies [29][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver sustained growth through commercial execution and innovation [6] - The guidance for 2026 anticipates total revenue in the range of $12.95 billion to $13.1 billion, representing 8%-9% growth versus the prior year [38] - The company expects combined non-GAAP operating expenses to be in the range of $5.65 billion to $5.75 billion as it continues to invest in its late-stage clinical pipeline [39] Other Important Information - The company has initiated a rolling BLA submission for povetacicept in IgAN, with breakthrough therapy designation granted by the FDA [11][12] - The company plans to double the size of its field force for JOURNAVX in Q2 2026 to drive prescription growth [26] Q&A Session Summary Question: Concerns about hypogammaglobulinemia adverse events related to pove - Management indicated that while low IgG levels are expected, data from the RUBY-3 study showed no serious adverse events or infections associated with low IgG levels, suggesting a favorable benefit-risk profile [43][44] Question: Guidance details for CF component and ALYFTREK performance - Management provided total revenue guidance of $12.95 billion to $13.1 billion, with a non-CF contribution of $500 million or more, while noting strong international launch contributions for ALYFTREK [49][51][52] Question: Payer access and reimbursement for pove - Management reported positive engagements with payers, indicating strong interest in the product and ongoing discussions to ensure access [59][60] Question: Expected results on proteinuria for pove - Management emphasized the importance of proteinuria response magnitude, referencing RUBY-3 results as a benchmark for expected outcomes in the RAINIER trial [62][64] Question: Rationale for studying pove in generalized myasthenia gravis - Management highlighted the significant patient population and limitations of current treatments, positioning pove as a potentially superior option due to its mechanism of action [70][72]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported worldwide revenue of $1.26 billion, a 13% increase from $1.11 billion in Q4 2024, with organic growth at 12% [17] - U.S. revenue reached $892 million in Q4 2025, up 11% from $803 million in Q4 2024 [17] - International revenue grew 18% to $368 million in Q4 2025, with organic growth at 15% [18] - Gross profit for Q4 was $799.8 million, representing 63.5% of revenue, an increase from 59.4% in Q4 2024 [19] - Operating income was $331.5 million, or 26.3% of revenue, compared to $209.5 million, or 18.8% of revenue, in Q4 2024 [20] - Adjusted EBITDA for Q4 was $422.2 million, or 33.5% of revenue, up from $300.1 million, or 27.0% of revenue, in Q4 2024 [20] - The company closed the quarter with approximately $2 billion in cash and cash equivalents, indicating strong financial flexibility [21] Business Line Data and Key Metrics Changes - The rollout of the Dexcom G7 15-day system has received positive feedback, enhancing customer experience and potentially increasing market share [8][9] - The company is focusing on improving customer experience through new digital support systems and AI integration [9][10] - The early access launch of Dexcom Smart Basal aims to improve outcomes for Type 2 diabetes management [10] Market Data and Key Metrics Changes - International markets, particularly Germany, the UK, and France, showed strong growth, with France being one of the fastest-growing markets due to Type 2 access expansion [18] - The company plans to expand its CGM product portfolio in international markets in 2026, targeting new segments [14] Company Strategy and Development Direction - The company aims to be the premier glucose sensing solution, focusing on sensor accuracy, reliability, and connectivity [7][8] - Strategic priorities include enhancing customer experience, expanding international market share, and driving growth through product innovation [12][14] - The company is preparing for an Investor Day in May 2026 to provide further outlook details [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in metabolic health and the impact of CGM technology on patient outcomes [28] - The company anticipates total revenue for 2026 to be between $5.16 billion and $5.25 billion, reflecting growth of 11%-13% [22] - Management highlighted the importance of maintaining strong category growth and expanding CGM access globally [23] Other Important Information - The company has successfully managed supply chain challenges, leading to improved gross margins and reduced sensor deployment issues [15] - The launch of the new patch technology is expected to enhance customer experience across the product portfolio [11] Q&A Session Summary Question: Discussion on glucose journey and market potential - Management believes the company is in the early stages of addressing metabolic health and sees significant growth opportunities, especially with potential Medicare coverage for Type 2 non-insulin users [26][28] Question: CMS proposal for Type 2 non-insulin coverage - Management is optimistic about upcoming CMS coverage decisions and expects to see positive outcomes from ongoing clinical trials [32][35] Question: Impact of the 15-day product on margins and market expansion - The 15-day product is expected to contribute to margins over time, with significant opportunities for international market expansion [38][41] Question: Operating expenses and investment in manufacturing - The increase in operating expenses is primarily due to investments in the new Ireland manufacturing facility, which will enhance production capabilities [46][48] Question: Utilization rates among different user segments - Utilization rates remain stable across various user segments, with high engagement expected to drive further growth [52][54] Question: Revenue outlook and new patient dynamics - Management provided insights into the factors influencing revenue growth, emphasizing the importance of patient retention and utilization [60][62] Question: Strengthening U.S. sensor uptake trends - Improved sensor deployment and the launch of new products have positively impacted sell-through trends, contributing to stable user retention [68][70] Question: Pricing dynamics with potential Medicare unlock - Management discussed the stable pricing environment and the impact of competitive bidding processes on future pricing strategies [75][78] Question: International growth strategy and competition - The company aims to close the revenue gap with competitors by expanding its product portfolio and increasing market penetration in international markets [82][84]

CVRx (NasdaqGS:CVRX) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsJared Oasheim - CFOKevin Hykes - President and CEOMike Vallie - Healthcare Investor Relations Managing DirectorConference Call ParticipantsChase Knickerbocker - Senior Equity Research AnalystFrank Takkinen - Senior Research AnalystJohn Young - Research AnalystLily Lozada - Research AnalystMax Smock - Equity Research AnalystNone - AnalystOperatorWelcome to the CVRx Q4 2025 Earnings Call. At this time, all participant ...

Sensus Healthcare (NasdaqCM:SRTS) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsAnthony Vendetti - Executive Managing DirectorBen Haynor - Managing Director of Medical Technology ResearchJavier Rampolla - CFOJoe Sardano - Chairman and CEOMichael Sardano - President & Chief Commercial OfficerTirth Patel - VPOperatorGood afternoon, and welcome to the Sensus Healthcare Fourth Quarter and Full Year 2025 Financial Results Conference Call. All participants will be in listen-only mode. Sh ...

SPS Commerce (NasdaqGS:SPSC) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsChad Collins - CEOIrmina Blaszczyk - Director of Investor RelationsKim Nelson - CFOConference Call ParticipantsChris Quintero - Equity Research AnalystDylan Becker - Equity Research AnalystGeorge Kurosawa - Equity Research AnalystJeff Van Rhee - Equity Research AnalystLachlan Brown - AnalystMatt VanVliet - Equity Research AnalystMatthew Kikkert - Associate AnalystNehal Chokshi - Equity Research AnalystScott ...